PIK3CA and non-small cell lung carcinoma: These results show that subclonal levels of PIK3CA mutations, which could be acquired during previous lines of therapies with first/second generation of EGFR-TKIs in patients with advanced-stage EGFR-mutant NSCLC, might have important therapeutic implications.